MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bouaboula, M.
Right arrow Articles by Casellas, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bouaboula, M.
Right arrow Articles by Casellas, P.

Vol. 55, Issue 3, 473-480, March 1999

Gi Protein Modulation Induced by a Selective Inverse Agonist for the Peripheral Cannabinoid Receptor CB2: Implication for Intracellular Signalization Cross-Regulation.

Monsif Bouaboula, Nathalie Desnoyer, Pierre Carayon, Thérèse Combes, and Pierre Casellas

Sanofi Recherche, Montpellier cedex 04, France

The peripheral cannabinoid receptor (CB2) is a G protein-coupled receptor that is both positively and negatively coupled to the mitogen-activated protein kinase (MAPK) and cAMP pathways, respectively, through a Bordetella pertussis toxin-sensitive G protein. CB2 receptor-transfected Chinese hamster ovary cells exhibit high constitutive activity blocked by the CB2-selective ligand, SR 144528, working as an inverse agonist. We showed here that in addition to the inhibition of autoactivated CB2 in this model, we found that SR 144528 inhibited the MAPK activation induced by Gi-dependent receptors such as receptor-tyrosine kinase (insulin, insulin-like growth factor 1) or G protein-coupled receptors (lysophosphatidic acid), but not by Gi-independent receptors such as the fibroblast growth factor receptor. We showed that this SR 144528 inhibitory effect on Gi-dependent receptors was mediated by a direct Gi protein inhibition through CB2 receptors. Indeed, we found that through binding to the CB2 receptors, SR 144528 blocked the direct activation of the Gi protein by mastoparan analog in Chinese hamster ovary CB2 cell membranes. Furthermore, we described that sustained treatment with SR 144528 induced an up-regulation of the cellular Gi protein level as shown in Western blotting as well as in confocal microscopic experiments. This up-regulation occurred with a concomitant loss of SR 144528 ability to inhibit the insulin or lysophosphatidic acid-induced MAPK activation. This inverse agonist-induced modulation of the Gi strongly suggests that the modulated protein is functionally associated with the complex SR 144528/CB2 receptors, and that the Gi level may account for the heterologous desensitization phenomena.

Copyright © 1999 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
F. Montecucco, F. Burger, F. Mach, and S. Steffens
CB2 cannabinoid receptor agonist JWH-015 modulates human monocyte migration through defined intracellular signaling pathways
Am J Physiol Heart Circ Physiol, March 1, 2008; 294(3): H1145 - H1155.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
C. A. Lunn, J. S. Fine, A. Rojas-Triana, J. V. Jackson, X. Fan, T. T. Kung, W. Gonsiorek, M. A. Schwarz, B. Lavey, J. A. Kozlowski, et al.
A Novel Cannabinoid Peripheral Cannabinoid Receptor-Selective Inverse Agonist Blocks Leukocyte Recruitment in Vivo
J. Pharmacol. Exp. Ther., February 1, 2006; 316(2): 780 - 788.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
G. K. Rao, W. Zhang, and N. E. Kaminski
Cannabinoid receptor-mediated regulation of intracellular calcium by {Delta}9-tetrahydrocannabinol in resting T cells
J. Leukoc. Biol., May 1, 2004; 75(5): 884 - 892.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
T. Kenakin
Efficacy as a Vector: the Relative Prevalence and Paucity of Inverse Agonism
Mol. Pharmacol., January 1, 2004; 65(1): 2 - 11.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
K. Wenzel-Seifert and R. Seifert
Molecular Analysis of beta 2-Adrenoceptor Coupling to Gs-, Gi-, and Gq-Proteins
Mol. Pharmacol., November 1, 2000; 58(5): 954 - 966.
[Abstract] [Full Text]

Home page
 Exp. Biol. Med.Home page
T. W. Klein, B. Lane, C. A. Newton, and H. Friedman
The Cannabinoid System and Cytokine Network
Experimental Biology and Medicine, October 1, 2000; 225(1): 1 - 8.
[Abstract] [Full Text]

Home page
 J. Immunol.Home page
L. X. Zhu, S. Sharma, M. Stolina, B. Gardner, M. D. Roth, D. P. Tashkin, and S. M. Dubinett
{Delta}-9-Tetrahydrocannabinol Inhibits Antitumor Immunity by a CB2 Receptor-Mediated, Cytokine-Dependent Pathway
J. Immunol., July 1, 2000; 165(1): 373 - 380.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
G. Chen, J. Way, S. Armour, C. Watson, K. Queen, C. K. Jayawickreme, W.-J. Chen, and T. Kenakin
Use of Constitutive G Protein-Coupled Receptor Activity for Drug Discovery
Mol. Pharmacol., January 1, 2000; 57(1): 125 - 134.
[Abstract] [Full Text]

Home page
 J. Neurosci.Home page
C. Vasquez and D. L. Lewis
The CB1 Cannabinoid Receptor Can Sequester G-Proteins, Making Them Unavailable to Couple to Other Receptors
J. Neurosci., November 1, 1999; 19(21): 9271 - 9280.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
M. Bouaboula, D. Dussossoy, and P. Casellas
Regulation of Peripheral Cannabinoid Receptor CB2 Phosphorylation by the Inverse Agonist SR 144528. IMPLICATIONS FOR RECEPTOR BIOLOGICAL RESPONSES
J. Biol. Chem., July 16, 1999; 274(29): 20397 - 20405.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1999 by the American Society for Pharmacology and Experimental Therapeutics